Stephen M. Campbell, MD; Richard Wernick, MD
Campbell S., Wernick R.; Update in Rheumatology. Ann Intern Med. 1999;130:135-142. doi: 10.7326/0003-4819-130-2-199901190-00008
Download citation file:
Published: Ann Intern Med. 1999;130(2):135-142.
The 1997 literature included important information on new treatment approaches to rheumatoid arthritis and ways to moderate the potentially toxic effects of antirheumatic drugs. The literature also contained several useful reports on state-of-the-art laboratory testing and a topic of perennial interest to all physicians—low back pain. Finally, we selected a “grab bag” of papers covering diverse rheumatologic topics that matter to practicing internists.
Much remains to be learned about the cause and pathogenesis of rheumatoid arthritis, but we have learned enough to begin to develop rational treatment strategies. Developments in 1997 included the use of tetracyclines to affect collagenase activity or immune function and aggressive early multidrug therapy to “turn off” early rheumatoid arthritis. Another approach—use of soluble recombinant human tumor necrosis factor (TNF) receptor—is predicated on the view that immunologic factors and cytokines contribute to the pathogenesis of rheumatoid arthritis.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only